Poor medication adherence tracked with worse day-to-day wellbeing in cardiovascular patients
Cardiovascular care often fails at the point where prescriptions leave the clinic. In a cohort of 465 patients seen at a cardiology clinic in Gryfice, Poland, adherence to treatment recommendations was generally poor to average, and only 35.1% said they took medication exactly as prescribed. The study focused on a practical question with direct bedside consequences: whether the way patients follow treatment advice relates to how they feel and function in daily life.
The answer was yes, but in a subtle and clinically useful way. Better adherence, measured with lower scores on the Adherence to Refills and Medications Scale (ARMS), was associated with better quality of life in the Psychological domain and the Environment domain of the WHOQOL-BREF, and the relationship persisted after adjustment for age, sex, comorbidity burden, and socioeconomic factors. A weak positive association also appeared between adherence and life satisfaction on the Satisfaction with Life Scale (SWLS).
That pattern matters because adherence in chronic cardiovascular disease is rarely an isolated behavior. Patients who miss medicines often do so in the setting of anxiety, limited health literacy, competing demands, financial strain, or low confidence that treatment will help. The Polish cohort reflected that reality: 90.8% of participants were receiving pharmacotherapy, yet more than half were not fully adherent. When a treatment plan is this common and nonadherence is this frequent, the gap is unlikely to be explained by a single missed dose or an occasional lapse. It points to a broader mismatch between long-term disease management and the realities of patients’ daily lives.
Medication adherence and quality of life can move in both directions. A patient who understands the purpose of therapy, experiences fewer symptoms, and feels supported by the healthcare system may take medication more reliably. At the same time, consistent use of cardiovascular therapy may stabilize symptoms, reduce fear of deterioration, and make daily life feel more manageable. The study does not prove which direction dominates, but the association is clinically plausible on both sides of the equation.
Psychological burden and environment shaped adherence more than the prescription itself
The strongest relationship appeared in the Psychological quality-of-life domain. That is clinically intuitive. Adherence in cardiovascular disease depends not just on drug availability or dosing schedules, but on memory, motivation, perceived benefit, and the emotional cost of living with chronic illness. Depression, distress, and uncertainty can erode the discipline needed to keep taking medicines every day, especially when symptoms are intermittent and the patient does not feel acutely ill.
Environmental quality of life also correlated with adherence. In practical terms, this domain captures the everyday conditions around the patient: access to care, household stability, finances, and the broader setting in which treatment is carried out. A regimen that looks simple in a chart can become difficult when a patient faces transport barriers, limited resources, or a fragmented healthcare system. Those are not abstract social variables; they are the setting in which adherence either holds or falls apart.
The study used a self-designed questionnaire alongside standardized tools, including WHOQOL-BREF, ARMS, Adherence in Chronic Diseases Scale (ACDS), and SWLS. Pharmacotherapy dominated treatment exposure in the sample, but the abstract does not provide details on specific drug classes, disease subtypes, or symptom burden. Even without those details, the central signal is hard to miss: patients who adhered better tended to report better psychological and environmental well-being.
Poor adherence is not just a marker of noncompliance. It can be a surrogate for the hidden friction between chronic disease management and lived experience.
What this means for cardiology clinics and chronic disease counseling
The findings support a familiar but often underused clinical principle: adherence should be treated as part of the cardiovascular assessment, not as a moral judgment delivered after the visit. If medication use and quality of life are linked, then conversations about pills need to include more than dose and timing. Clinicians need to ask whether the patient believes the treatment works, whether side effects or pill burden are getting in the way, and whether home circumstances make long-term self-management realistic.
This study also suggests that quality of life instruments may help identify patients at risk for poor adherence. A patient struggling in the psychological or environmental domains may need more than a prescription renewal. Education, simplification of regimens where possible, reinforcement of treatment goals, and attention to social barriers may improve the odds that prescribed therapy is actually used.
The sample came from a single cardiology clinic, so the findings reflect a real outpatient population rather than a highly selected trial cohort. That increases their clinical face validity, but it also limits how broadly the results can be applied. The abstract does not provide enough detail to determine whether the observed associations differ by specific cardiovascular diagnosis, disease severity, or treatment type. It also does not measure whether improving adherence would directly improve quality of life, only that the two move together in this cohort.
Even with those limits, the practical message is direct. Cardiovascular outcomes depend not only on what is prescribed, but on what patients can sustain. When adherence slips, quality of life often slips with it. When quality of life is poor, adherence may be the first visible sign that the treatment plan has become too hard to carry.
A chronic disease problem that reaches beyond the prescription pad
The investigators concluded that patients with cardiovascular disease were characterized by poor to average adherence to treatment recommendations, and that medication adherence appeared to be associated with quality of life. The study received no external funding and reported no competing interests, with ethics approval from the Bioethical Committee of Pomeranian Medical University in Szczecin.
The unresolved question is not whether adherence matters; it plainly does. The harder clinical task is identifying which part of the patient’s life is driving the breakdown, because in chronic cardiovascular disease, the barrier is often psychological, social, and practical long before it becomes pharmacologic.